Concepedia
Statistics
Publications
8
Citations
264
H-Index
Active since
1996
Affiliations
National Institute of Oncology(Current)
Hungarian Academy of Sciences
Semmelweis University
University of Konstanz
Eötvös Loránd University
Miguel Tejeda is an author at National Institute of Oncology specializing in oncology, medicine, and cancer pharmacology.
Publications per year
1996–2011
A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity.
G Kéri, J. Érchegyi, Anikó Horváth et al. · Proceedings of the National Academy of Sciences · 1996 · 98 citations · Full text
Medicine, Oncology, Pharmacology +7
Development of an Oxime Bond Containing Daunorubicin-Gonadotropin-Releasing Hormone-III Conjugate as a Potential Anticancer Drug
Ildikó Szabó, Marilena Manea, Erika Orbán et al. · Bioconjugate Chemistry · 2009 · 64 citations
Medicine, Oncology, Pharmacology +9
Enhanced Enzymatic Stability and Antitumor Activity of Daunorubicin-GnRH-III Bioconjugates Modified in Position 4
Marilena Manea, Ulrike Leurs, Erika Orbán et al. · Bioconjugate Chemistry · 2011 · 32 citations
Medicine, Biochemistry, Oncology +14
In-vivo antitumour effect of daunorubicin–GnRH-III derivative conjugates on colon carcinoma-bearing mice
Marilena Manea, József Tóvári, Miguel Tejeda et al. · Anti-Cancer Drugs · 2011 · 20 citations
Medicine, Oncology, Pharmacology +17
The antitumor activity of the somatostatin structural derivative (TT-232) on different human tumor xenografts.
Miguel Tejeda, D. Gaál, Krisztina Barna et al. · PubMed · 2004 · 16 citations
Medicine, Oncology, Pharmacology +15
1–5 of 8